These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 12153370)

  • 21. Trends in the Use of Guideline-Directed Therapies Among Dialysis Patients Hospitalized With Systolic Heart Failure: Findings From the American Heart Association Get With The Guidelines-Heart Failure Program.
    Pandey A; Golwala H; DeVore AD; Lu D; Madden G; Bhatt DL; Schulte PJ; Heidenreich PA; Yancy CW; Hernandez AF; Fonarow GC
    JACC Heart Fail; 2016 Aug; 4(8):649-61. PubMed ID: 27179827
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minority Representation in Migraine Treatment Trials.
    Robbins NM; Bernat JL
    Headache; 2017 Mar; 57(3):525-533. PubMed ID: 28127754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study: rationale and design.
    Santhanakrishnan R; Ng TP; Cameron VA; Gamble GD; Ling LH; Sim D; Leong GK; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Lund M; Devlin G; Troughton R; Richards AM; Doughty RN; Lam CS
    J Card Fail; 2013 Mar; 19(3):156-62. PubMed ID: 23482075
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Right ventricular function in heart failure with preserved ejection fraction: a community-based study.
    Mohammed SF; Hussain I; AbouEzzeddine OF; Takahama H; Kwon SH; Forfia P; Roger VL; Redfield MM
    Circulation; 2014 Dec; 130(25):2310-20. PubMed ID: 25391518
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure.
    Wolsk E; Claggett B; Køber L; Pocock S; Yusuf S; Swedberg K; McMurray JJV; Granger CB; Pfeffer MA; Solomon SD
    Eur J Heart Fail; 2018 Mar; 20(3):504-510. PubMed ID: 29193462
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Hospitalization Burden and Post-Hospitalization Mortality Risk in Heart Failure With Preserved Ejection Fraction: Results From the I-PRESERVE Trial (Irbesartan in Heart Failure and Preserved Ejection Fraction).
    Carson PE; Anand IS; Win S; Rector T; Haass M; Lopez-Sendon J; Miller A; Teerlink JR; White M; McKelvie RS; Komajda M; Zile MR; McMurray JJ; Massie B
    JACC Heart Fail; 2015 Jun; 3(6):429-441. PubMed ID: 25982110
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chronic heart failure].
    Hradec J
    Cas Lek Cesk; 2015; 154(6):260-8. PubMed ID: 26750621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multi-ethnic comparisons of diabetes in heart failure with reduced ejection fraction: insights from the HF-ACTION trial and the ASIAN-HF registry.
    Cooper LB; Yap J; Tay WT; Teng TK; MacDonald M; Anand IS; Sharma A; O'Connor CM; Kraus WE; Mentz RJ; Lam CS;
    Eur J Heart Fail; 2018 Sep; 20(9):1281-1289. PubMed ID: 29943890
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of glomerular filtration rate estimation equations in acute heart failure with preserved versus reduced ejection fraction.
    Casado Cerrada J; Carrasco Sánchez FJ; Pérez-Calvo JI; Manzano L; Formiga F; Aramburu Bodas O; Conde A; Quirós R; Pérez Bocanegra C; Montero-Pérez-Barquero M;
    Int J Clin Pract; 2015 Aug; 69(8):829-39. PubMed ID: 25651522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testosterone supplementation in heart failure: a meta-analysis.
    Toma M; McAlister FA; Coglianese EE; Vidi V; Vasaiwala S; Bakal JA; Armstrong PW; Ezekowitz JA
    Circ Heart Fail; 2012 May; 5(3):315-21. PubMed ID: 22511747
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Does natriuretic peptide monitoring improve outcomes in heart failure patients? A systematic review and meta-analysis.
    Khan MS; Siddiqi TJ; Usman MS; Sreenivasan J; Fugar S; Riaz H; Murad MH; Mookadam F; Figueredo VM
    Int J Cardiol; 2018 Jul; 263():80-87. PubMed ID: 29685696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of outcomes and usefulness of carvedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice.
    Massie BM; Nelson JJ; Lukas MA; Greenberg B; Fowler MB; Gilbert EM; Abraham WT; Lottes SR; Franciosa JA;
    Am J Cardiol; 2007 May; 99(9):1263-8. PubMed ID: 17478155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical characteristics and prognosis of heart failure with normal left ventricular ejection fraction in elderly patients.
    Liu DP; Wang F; Zeng XZ; Zhang XC
    Chin Med J (Engl); 2012 Aug; 125(16):2853-7. PubMed ID: 22932079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
    Shah RV; Desai AS; Givertz MM
    J Card Fail; 2010 Mar; 16(3):260-7. PubMed ID: 20206902
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity).
    Wong CM; Hawkins NM; Jhund PS; MacDonald MR; Solomon SD; Granger CB; Yusuf S; Pfeffer MA; Swedberg K; Petrie MC; McMurray JJ
    J Am Coll Cardiol; 2013 Nov; 62(20):1845-54. PubMed ID: 23850914
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum.
    Lund LH; Claggett B; Liu J; Lam CS; Jhund PS; Rosano GM; Swedberg K; Yusuf S; Granger CB; Pfeffer MA; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2018 Aug; 20(8):1230-1239. PubMed ID: 29431256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcomes of heart failure with preserved ejection fraction in a Southeast Asian cohort.
    Hoong CW; Lim CP; Gao F; Chen Q; Kawa LB; Ching CK; Sim DK
    J Cardiovasc Med (Hagerstown); 2015 Sep; 16(9):583-90. PubMed ID: 25022929
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.